DARE News and Press, Dare Bioscience Inc. From 04/12/22

Prior Phase 1 Study Results Support Potential as the First Monthly Therapy for both the Vasomotor and the Vaginal Symptoms of Menopause Current Phase 1/2 Study will Collect Symptom Relief and Acceptability Data in Addition to Evaluating Pharm acokin etics over a Three-Mo...

Daré Bioscience, Inc. (DARE) Q4 2021 Earnings Conference Call March 31, 2022, 4:30 PM ET Company Participants Sabrina Martucci Johnson – President and Chief Executive Officer Lisa Walters-Hoffert – Chief Financial Officer John Fair – Chief Strategy Officer Conference...

Buying Penny Stocks Today? Here’s What You Need to Know With another day of trading penny stocks and blue chips here, there is a lot for investors to know. Recently, we’ve seen a bullish streak with 4 days of gains in the market. However, in the last day or so, this sentim...

Dare Bioscience press release (NASDAQ:DARE): FY GAAP EPS of -$0.63 misses by $0.03. Cash and cash equivalents of $51.7 million at December 31, 2021, compared to $4.7 million at December 31, 2020. Shares +13.6% PM. For further details see: Dare Bioscience GAAP EPS of -$0.63 misses by $0....

Clovis Oncology (CLVS) +45% meets key goal for ovarian cancer therapy in late-stage trial. Longeveron (LGVN) +36% publishes peer reviewed study of phase 1 trial results of Lomecel-B for alzheimer’s disease in alzheimer’s & dementia: the journal of the alzheime...

Clinica-stage biopharma company, Daré Bioscience (NASDAQ:DARE), has added ~18% in the pre-market Thursday on the announcement of an agreement with women’s healthcare company Organon (NYSE:OGN) for Xaciato, an FDA-approved therapy for bacterial vaginosis. Xaciato, also kn...

Entered into an exclusive global license agreement with Organon to commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%) that includes a $10 million upfront cash payment once effective U.S. commercial launch of XACIATO expected in 4Q-2022 Initiated co...

An estimated 21 million American women experience BV Organon (NYSE: OGN), a global women’s healthcare company, and Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced they have entered into an agreement whereby Orga...

Dare Bioscience (NASDAQ:DARE) is scheduled to announce FY earnings results on Thursday, March 31st, after market close. The consensus EPS Estimate is -$0.71 (+22.0% Y/Y) and the consensus Revenue Estimate is $1.25M. For further details see: Dare Bioscience FY 2021 Earnings Preview

ADMP, AEHR, ASTR, ASTS, BB, BIOC, BLND, CALA, DARE, DCT, FUV, MARK, NBEV, NCNO, NVVE, PL, PL, PPSI, REED, REKR, OTCQX:SHWZ, SPRO, OTCQX:TPRFF, VERB, VISL, VJET, VTSI For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Thursday's...